A multicenter, randomized, controlled, open-label, phase 2 study of the PD-1/IL-2 α-bias bispecific antibody fusion protein IBI363 in mucosal and acral melanoma.
Year: 2025
Type: conference-abstract
Source: Journal of Clinical Oncology
Authors: Bin Lian, Yu Chen, Zhiguo Luo, Xiaoshi Zhang, Di Wu, Ke Li, Zhengyun Zou, Meiyu Fang, Chen Jing, Huijing Feng, Yu Jiang, Weizhen Zhang, Xianan Li, Renbing Jiang, Enwen Wang, Cuihua Yi, Yinbin Zhang, Xueying Zhang, Xiubao Ren, Jun Guo
Institutions: Peking University Cancer Hospital, Fujian Provincial Cancer Hospital, Fudan University Shanghai Cancer Center, Jilin Province Tumor Hospital, Sun Yat-sen University Cancer Center, First Hospital of Jilin University, Nanjing Drum Tower Hospital, Zhejiang Cancer Hospital, Wuhan Union Hospital, Huazhong University of Science and Technology, West China Hospital of Sichuan University, Hunan Cancer Hospital, Xinjiang Medical University, Tumor Hospital of Xinjiang Medical University, Chongqing University, Chongqing Cancer Hospital, Qilu Hospital of Shandong University, Second Affiliated Hospital of Xi'an Jiaotong University, Tianjin Medical University Cancer Institute and Hospital
Language: English
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W4410817794